EYLEA(R) (aflibercept) Injection Demonstrates Significantly Greater Gains in Visual Acuity than Both Bevacizumab and Ranibizumab in NIH-Sponsored Diabetic Macular Edema Study
TARRYTOWN, N.Y., Oct. 17, 2014 -- (Healthcare Sales & Marketing Network) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that in the National Institutes of Health (NIH) sponsored, Diabetic Retinopathy Clinical Research Network (DRCR.net)... Biopharmaceuticals, OphthalmologyRegeneron Pharmaceuticals, EYLEA, aflibercept, Diabetic Macular Edema
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news
More News: Avastin | Diabetes | Endocrinology | Health | Lucentis | Marketing | National Institutes of Health (NIH) | Opthalmology | Pharmaceuticals | Ranibizumab Injection | Study